HK1026626A1 - Immunopotentiating formulations for vaccinal use. - Google Patents

Immunopotentiating formulations for vaccinal use.

Info

Publication number
HK1026626A1
HK1026626A1 HK00105771A HK00105771A HK1026626A1 HK 1026626 A1 HK1026626 A1 HK 1026626A1 HK 00105771 A HK00105771 A HK 00105771A HK 00105771 A HK00105771 A HK 00105771A HK 1026626 A1 HK1026626 A1 HK 1026626A1
Authority
HK
Hong Kong
Prior art keywords
immunopotentiating
formulations
vaccinal
vaccinal use
immunopotentiating formulations
Prior art date
Application number
HK00105771A
Other languages
English (en)
Inventor
Julio Cesar Aguilar Rubido
Verena Lucila Muzio Gonzalev
Maria De Jesus Leal Angulo
Gerardo Enrique Guillen Nieto
Eduardo Penton Arias
Gloria Veliz Rios
Dagmara Pichardo Diaz
Antonieta Herrera Buch
Enrique Iglesias Perez
Luis Javier Cruz Ricondo
Tania Carmenate Portilla
Cirse Mesa Pardillo
Maydel Hechavarria Gay
Maylin Diaz Martinez
Juan Joel Madrazo Pinol
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of HK1026626A1 publication Critical patent/HK1026626A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK00105771A 1997-03-06 2000-09-14 Immunopotentiating formulations for vaccinal use. HK1026626A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1997027A CU22629A1 (es) 1997-03-06 1997-03-06 Formulaciones inmunopotenciadoras para uso vacunal
PCT/CU1998/000003 WO1998039032A1 (es) 1997-03-06 1998-03-05 Formulaciones inmunopotenciadoras para uso vacunal

Publications (1)

Publication Number Publication Date
HK1026626A1 true HK1026626A1 (en) 2000-12-22

Family

ID=5459228

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105771A HK1026626A1 (en) 1997-03-06 2000-09-14 Immunopotentiating formulations for vaccinal use.

Country Status (15)

Country Link
US (1) US6355414B1 (es)
EP (1) EP0971737B1 (es)
CN (1) CN1161154C (es)
AR (1) AR009866A1 (es)
AT (1) ATE295182T1 (es)
AU (1) AU6607798A (es)
BR (1) BR9808832A (es)
CA (1) CA2283344A1 (es)
CU (1) CU22629A1 (es)
DE (1) DE69830156T2 (es)
ES (1) ES2241122T3 (es)
HK (1) HK1026626A1 (es)
MY (1) MY132817A (es)
WO (1) WO1998039032A1 (es)
ZA (1) ZA981897B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US20060105063A1 (en) * 2004-11-18 2006-05-18 Kent Hann Synergic combination of compositions containing aloe vera isolates and their therapeutic application
EP1948782B8 (en) 2005-04-25 2012-09-12 Cadila Pharmaceuticals Limited Vaccine adjuvants
CA2672338C (en) 2006-12-15 2017-06-06 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
DE69005572T2 (de) * 1989-09-08 1994-04-07 Takeda Chemical Industries Ltd Fusionsproteine und Herstellung davon.
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
PT835663E (pt) * 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JPH08183742A (ja) * 1994-12-28 1996-07-16 Dai Ichi Seiyaku Co Ltd 経鼻ワクチンリポソーム
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤

Also Published As

Publication number Publication date
CA2283344A1 (en) 1998-09-11
EP0971737A1 (en) 2000-01-19
US6355414B1 (en) 2002-03-12
CN1161154C (zh) 2004-08-11
WO1998039032A1 (es) 1998-09-11
EP0971737B1 (en) 2005-05-11
MY132817A (en) 2007-10-31
ES2241122T3 (es) 2005-10-16
AR009866A1 (es) 2000-05-03
CN1252002A (zh) 2000-05-03
DE69830156T2 (de) 2006-01-26
ZA981897B (en) 1998-09-07
AU6607798A (en) 1998-09-22
DE69830156D1 (de) 2005-06-16
BR9808832A (pt) 2000-07-04
ATE295182T1 (de) 2005-05-15
CU22629A1 (es) 2000-12-22

Similar Documents

Publication Publication Date Title
GB9715751D0 (en) Formulations
ZA9811848B (en) Vaccine.
ZA984969B (en) Vaccine.
ZA988789B (en) Vaccine.
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9713149D0 (en) Pharmaceutical formulations
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
ZA993338B (en) Pharmaceutical formulations.
ZA9810081B (en) Extended release formulation.
HK1040488A1 (en) Pharmaceutical formulations.
HK1026626A1 (en) Immunopotentiating formulations for vaccinal use.
GB9725061D0 (en) Revitalisation formulation
GB9706957D0 (en) Formulation
ZA982763B (en) Vaccines
ZA984696B (en) Vaccine compositions V.
GB9704521D0 (en) Formulations
GB9703099D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9703101D0 (en) Formulations
ZA972387B (en) Pharmaceutical formulations.
ZA9810587B (en) Anaesthetic formulation.
GB9703607D0 (en) Pharmaceutical formulations
ZA987303B (en) Vaccine.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090305